VEA
LJPC

Virtus ETF Advisers’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Virtus ETF Advisers’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,021
Closed -$229K – 532
2019
Q3 		$229K Sell
26,021
-1,449
-5% -$13.7K 0.05% 223
2019
Q2 		$254K Buy
+27,470
New +$207K 0.05% 271
2019
Q1 		– Sell
-23,806
Closed -$224K – 312
2018
Q4 		$224K Buy
23,806
+8,545
+56% +$129K 0.04% 173
2018
Q3 		$307K Sell
15,261
-10,919
-42% -$285K 0.03% 187
2018
Q2 		$764K Sell
26,180
-4,993
-16% -$154K 0.68% 59
2018
Q1 		$928K Buy
31,173
+16,779
+117% +$541K 0.81% 54
2017
Q4 		$463K Buy
14,394
+2,549
+22% +$83.3K 0.58% 44
2017
Q3 		$412K Buy
11,845
+1,084
+10% +$34.9K 0.06% 105
2017
Q2 		$320K Sell
10,761
-5,087
-32% -$146K 0.05% 109
2017
Q1 		$473K Buy
15,848
+1,519
+11% +$38.8K 0.08% 104
2016
Q4 		$251K Buy
14,329
+38
+0.3% +$728 0.08% 141
2016
Q3 		$340K Hold
14,291
– – 0.16% 88
2016
Q2 		$229K Buy
14,291
+4,646
+48% +$83.3K 0.17% 116
2016
Q1 		$202K Sell
9,645
-605
-6% -$10.8K 0.28% 81
2015
Q4 		$277K Buy
+10,250
New +$279K 0.76% 49

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtus ETF Advisers's LJPC Position: Q4 2019 in Review

Virtus ETF Advisers sold out of La Jolla Pharmaceutical Company (LJPC) in Q4 2019, closing a stake of 26,021 shares — an estimated $229K sold.

Virtus ETF Advisers first reported a position in LJPC in Q4 2015 and held it in 15 quarters. The position peaked at $928K in Q1 2018. 77 funds tracked by Wall St. Rank hold LJPC as of Q4 2019.

  • Virtus ETF Advisers reported no remaining La Jolla Pharmaceutical Company position as of Q4 2019 after selling out during the quarter.
  • Virtus ETF Advisers sold 26,021 La Jolla Pharmaceutical Company shares in Q4 2019, an estimated $229K.
  • Virtus ETF Advisers first reported a position in La Jolla Pharmaceutical Company in Q4 2015 and held it in 15 quarters.
  • Virtus ETF Advisers's La Jolla Pharmaceutical Company position peaked at $928K in Q1 2018.
  • 77 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q4 2019.

Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.